BIOLUX P-III All-Comers Passeo-18 Lux Registry

NCT ID: NCT02276313

Last Updated: 2022-08-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

880 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-10-31

Study Completion Date

2022-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

BIOLUX P-III is a prospective, international, multi-centre, postmarket all-comers registry to collect clinical performance data on the Passeo-18 Lux paclitaxel releasing balloon catheter in the treatment of atherosclerotic disease of the infrainguinal arteries.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Passeo-18 LUX Paclitaxel Releasing BalloonCatheter is a novel drug-releasing balloon that received CE-mark in January 2014. Its safety and efficacy has been investigated in two randomized First-in-Man trials in patients with stenosis or occlusion of the femoropopliteal (BIOLUX P-I) and infrapopliteal (BIOLUX P-II) arteries when compared to an uncoated device.

The purpose of the BIOLUX P-III all-comers registry is to collect short and long-term clinical performance data on the Passeo-18 Lux DRB in the treatment of atherosclerotic disease in the infrainguinal arteries in an all-comers patient population in daily clinical practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis Peripheral Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Passeo-18 Lux

Endovascular Therapy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years or minimum age as required by local regulations
* Subject must be willing to sign a Patient Data Release Form or Patient Informed Consent where applicable
* Lesion(s) in the infrainguinal arteries suitable for endovascular treatment treated with or scheduled to be treated with the Passeo-18 Lux drug releasing balloon

Exclusion Criteria

* Life expectancy ≤ 1 year
* Subject is currently participating in another investigational drug or device study that has not reached ist primary endpoint yet
* Subject is pregnant or planning to become pregnant during the course of the study
* Failure to successfully cross the target lesion with a guide wire (successful crossing means tip of the guide wire distal to the target lesion in the absence of flow limiting dissections or perforations
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biotronik AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gunnar Tepe, MD

Role: PRINCIPAL_INVESTIGATOR

RoMed Klinikum Rosenheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cairns Hospital

Cairns, , Australia

Site Status

Lake Macquarie Private Hospital

Gateshead, , Australia

Site Status

Geelong University Hospital

Geelong, , Australia

Site Status

Hollywood Hospital

Nedlands, , Australia

Site Status

The Townsville Hospital

Townsville, , Australia

Site Status

Medizinische Universität Graz

Graz, , Austria

Site Status

Department Radiologie, Universitätsklinik für Radiodiagnostik

Innsbruck, , Austria

Site Status

UCL St. Luc

Brussels, , Belgium

Site Status

UZ Leuven

Leuven, , Belgium

Site Status

CHR de la Citadelle

Liège, , Belgium

Site Status

Regionaal Ziekenhuis Heilig Hart Tienen

Tienen, , Belgium

Site Status

Kolding Hospital

Kolding, , Denmark

Site Status

Tampereen Yliopiostollinen Keskussariaaia

Tampere, , Finland

Site Status

CHU de Clermont-Ferrand

Clermont-Ferrand, , France

Site Status

Clinique Pasteur Essey Les Nancy

Essey-lès-Nancy, , France

Site Status

CHU de Grenoble

Grenoble, , France

Site Status

Hospices Civils de Lyon

Lyon, , France

Site Status

Klinikum Arnsberg, Karolinenhospital

Arnsberg, , Germany

Site Status

Department of Angiology at Universitats- Herzzentrum Freiburg

Bad Krozingen, , Germany

Site Status

Gemeinschaftspraxis für Radiologie

Berlin, , Germany

Site Status

Sank Gertrauden-Krankenhaus

Berlin, , Germany

Site Status

Universitätsklinikum Giessen und Marburg GmbH

Giessen, , Germany

Site Status

Herz- und Gefässzentrum Göttingen

Göttingen, , Germany

Site Status

Universitätsklinikum Jena

Jena, , Germany

Site Status

Universitätsklinikum Schleswig-Holstein

Kiel, , Germany

Site Status

Kliniken München Pasing-Perlach GmbH

München Pasing, , Germany

Site Status

RoMed Klinikum Rosenheim

Rosenheim, , Germany

Site Status

Ospedale San Giovanni di Dio

Florence, , Italy

Site Status

Policlinico San Donato

San Donato Milanese, , Italy

Site Status

P.Stradins Clinical University Hospital, Institute of Diagnostic

Riga, , Latvia

Site Status

Institute Jantung Negara

Kuala Lumpur, , Malaysia

Site Status

Catharina Hospital

Eindhoven, , Netherlands

Site Status

Saint Elisabeth Hospital

Tilburg, , Netherlands

Site Status

Hospital Garcia de Orta

Almada, , Portugal

Site Status

Changi General Hospital

Singapore, , Singapore

Site Status

Singapore General Hospital

Singapore, , Singapore

Site Status

Tan Tock Seng Hospital

Singapore, , Singapore

Site Status

Institute of Cardiovascular diseases Kosice, Dpt. of Angiology

Košice, , Slovakia

Site Status

Hospital. Universitario Germans Trias i Pujol

Badalona, , Spain

Site Status

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Site Status

Hospital Clinico San Carlos

Madrid, , Spain

Site Status

Hospital Universitario Severo Ochoa

Madrid, , Spain

Site Status

Centre Hopsitalier Universitaire Vaudois

Lausanne, , Switzerland

Site Status

Ospedale Regionale di Lugano

Lugano, , Switzerland

Site Status

KS Winterthur

Winterthur, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Austria Belgium Denmark Finland France Germany Italy Latvia Malaysia Netherlands Portugal Singapore Slovakia Spain Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Dodd JE, Hanna J, Brodmann M, Golledge J, Zeller T, Moscovic M, Dahm J, Troisi N, Tepe G, Wong J, Ward NC, Mwipatayi BP. Outcomes of drug-coated balloon angioplasty in patients with dyslipidemia in the BIOLUX P-III registry: A subgroup analysis. Vascular. 2024 Aug 19:17085381241275795. doi: 10.1177/17085381241275795. Online ahead of print.

Reference Type DERIVED
PMID: 39158589 (View on PubMed)

Barry IP, Macarulay R, Brodmann M, Zeller T, Moscovic M, Dahm J, Troisi N, Tepe G, Wong J, Mwipatayi BP; BIOLUX P-III Global Registry Investigators. Sex-Related Outcomes Following Drug Balloon Angioplasty in Patients from the BIOLUX P-III Registry: A Subgroup Analysis. Cardiovasc Intervent Radiol. 2022 Jul;45(7):918-928. doi: 10.1007/s00270-022-03135-w. Epub 2022 Apr 20.

Reference Type DERIVED
PMID: 35445317 (View on PubMed)

Mwipatayi BP, Barry IP, Brodmann M, Zeller T, Varcoe RL, Moscovic M, Chian JWC, Christensen JK, Yahaya SA, Oshin OA, Tepe G; BIOLUX P-III Global Registry Investigators. Twenty-Four-Month Outcomes of Drug-Coated Balloon in Diabetic Patients in the BIOLUX P-III Registry: A Subgroup Analysis. Ann Vasc Surg. 2021 Aug;75:237-252. doi: 10.1016/j.avsg.2021.02.050. Epub 2021 Apr 5.

Reference Type DERIVED
PMID: 33831519 (View on PubMed)

Tepe G, Zeller T, Moscovic M, Corpataux JM, Christensen JK, Keirse K, Nano G, Schroeder H, Binkert CA, Brodmann M. Paclitaxel-Coated Balloon Angioplasty for the Treatment of Infrainguinal Arteries: 24-Month Outcomes in the Full Cohort of BIOLUX P-III Global Registry. Cardiovasc Intervent Radiol. 2021 Feb;44(2):207-217. doi: 10.1007/s00270-020-02663-7. Epub 2020 Oct 20.

Reference Type DERIVED
PMID: 33083853 (View on PubMed)

Tepe G, Wang J, Corpataux JM, Pua U, Binkert CA, Moscovic M, Ghotbi R, Keirse K, Robertson D, Brodmann M. BIOLUX P-III Passeo-18 Lux All-Comers Registry: 24-Month Results in Below-the-Knee Arteries. Cardiovasc Intervent Radiol. 2021 Jan;44(1):10-18. doi: 10.1007/s00270-020-02586-3. Epub 2020 Sep 22.

Reference Type DERIVED
PMID: 32964317 (View on PubMed)

Tepe G, Zeller T, Moscovic M, Corpataux JM, Christensen JK, Keirse K, Nano G, Schroeder H, Binkert CA, Brodmann M. Paclitaxel-Coated Balloon for the Treatment of Infrainguinal Disease: 12-Month Outcomes in the All-Comers Cohort of BIOLUX P-III Global Registry. J Endovasc Ther. 2020 Apr;27(2):304-315. doi: 10.1177/1526602819898804. Epub 2020 Jan 28.

Reference Type DERIVED
PMID: 31989855 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C1211

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BRight DCB First-in-Human Study
NCT04525794 COMPLETED NA
e-BioMatrix PostMarket Registry
NCT01289002 COMPLETED
TORUS 2 IDE Clinical Study
NCT04130737 ACTIVE_NOT_RECRUITING NA